Drug
Garsorasib clinical trials
- studies test it
- 9
- open now
- 4
- in phase 3
- 1
- first study started
- 2021
Keep track of what changes. Save the garsorasib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Combined with it in one product
Studies by the year they started
9 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 3
InventisBio Co., Ltd (5) · Sun Yat-sen University (1) · Suzhou Genhouse Bio Co., Ltd. (1) · Guangdong Provincial People's Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Often tested with
Tested in the same studies.
Ifebemtinib (1) · Benmelstobart (1) · Anlotinib (1) · Cetuximab (1) · GH21 (1) · Ivonescimab (1)
Studies
Open first, then newest update. How each study uses garsorasib is read from its arms, and is right about nine times in ten.
Testing it · 9
- Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)RecruitingPhase 2Guangdong Provincial People's HospitalNCT07472478Written as Garsorasib
- Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLCNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07294261Written as Garsorasib, Benmelstobart, Anlotinib
- GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid TumorsNot yet recruitingPhase 1/2Suzhou Genhouse Bio Co., Ltd.NCT06435455Written as D-1553
- D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy FailureRecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06300177Written as D-1553 Tablet
- Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid TumorsActive, not recruitingPhase 1/2InventisBio Co., LtdNCT05379946Written as D-1553
- A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole on PK of D-1553CompletedPhase 1InventisBio Co., LtdNCT06105255Written as D-1553
- Study to Evaluate D-1553 in Subjects With Lung CancerCompletedPhase 1/2InventisBio Co., LtdNCT05383898Written as D-1553
- A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung CancerTerminatedPhase 1/2InventisBio Co., LtdNCT05492045Written as D-1553
- Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male SubjectsCompletedPhase 1InventisBio Co., LtdNCT06233916Written as [14C] D-1553
Given in every arm · 2 — garsorasib is usual care beside what is tested
- a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid TumorsActive, not recruitingPhase 1/2InxMed (Shanghai) Co., Ltd.NCT06166836Written as D1553
- Study to Evaluate D-1553 in Subjects With Solid TumorsActive, not recruitingPhase 1/2InventisBio Co., LtdNCT04585035Written as D-1553
As the comparator · 1 — what is tested is compared with garsorasib
Codes
What other systems call garsorasib · ClinicalTrials.gg INT017537
- UNII (FDA) P491NE9G6ZGARSORASIBConfirmed FDA, Wikidata
- Wikidata Q137767962garsorasibConfirmed FDA, Wikidata
- NCI Thesaurus C178562GarsorasibOne source FDA
- DrugBank DB21581One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | P491NE9G6Z | GARSORASIB | Confirmed FDA, Wikidata |
| Wikidata | Q137767962 | garsorasib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C178562 | Garsorasib | One source FDA |
| DrugBank | DB21581 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.